The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 17, 2019

Filed:

Nov. 07, 2017
Applicant:

Procella Therapeutics Ab, Tullinge, SE;

Inventors:

Kenneth R. Chien, Cambridge, MA (US);

Jonathan Clarke, Stockholm, SE;

Miia Lehtinen, Tuusula, FI;

Kylie Foo, Stockholm, SE;

Chuen Yan Leung, Stockholm, SE;

Assignee:

Procella Therapeutics AB, Tullinge, SE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/077 (2010.01); A61K 35/34 (2015.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0657 (2013.01); A61K 35/34 (2013.01); G01N 33/5014 (2013.01); G01N 33/5061 (2013.01); C12N 2501/415 (2013.01); C12N 2501/42 (2013.01); C12N 2501/50 (2013.01); C12N 2501/599 (2013.01); C12N 2501/727 (2013.01); C12N 2506/02 (2013.01); C12N 2506/45 (2013.01); C12N 2513/00 (2013.01);
Abstract

The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.


Find Patent Forward Citations

Loading…